Medications

A new drug target for liver cancer

National University of Singapore researchers have discovered that the MOAP-1 protein plays a role in reducing liver cancer risk by suppressing the hyper-active cancer-promoting Nrf2 cellular signaling pathway.

Oncology & Cancer

Armoring anti-cancer T cells against immunosuppressants

Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant ...

Oncology & Cancer

Cell environment influences type of liver tumor

Liver cancer is the second leading cause of cancer death worldwide. Two forms of primary liver cancer cover the majority of cases: About 10 to 20 percent of those affected develop a bile duct carcinoma within the liver (intrahepatic ...

Oncology & Cancer

Researchers discover new anti-cancer protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from ...

Oncology & Cancer

Researchers identify UHRF1 as oncogene driving liver cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data ...

page 1 from 13